Sageworth Trust Co Has $2.86 Million Stake in Abbott Laboratories $ABT

Posted by Brenda Bartman on Jul 9th, 2026

Sageworth Trust Co grew its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 36.7% in the 1st quarter, Holdings Channel reports. The fund owned 27,828 shares of the healthcare product maker’s stock after purchasing an additional 7,470 shares during the quarter. Sageworth Trust Co’s holdings in Abbott Laboratories were worth $2,857,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of ABT. Cornerstone Financial Management LLC bought a new stake in Abbott Laboratories during the 4th quarter worth approximately $25,000. MidAtlantic Capital Management Inc. bought a new position in Abbott Laboratories in the fourth quarter valued at approximately $25,000. Purpose Unlimited Inc. bought a new position in Abbott Laboratories in the fourth quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. acquired a new position in shares of Abbott Laboratories in the fourth quarter valued at approximately $26,000. Finally, Abound Financial LLC bought a new stake in shares of Abbott Laboratories during the fourth quarter worth $26,000. Institutional investors own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

ABT has been the topic of several research reports. Barclays cut their price objective on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a research report on Monday, April 20th. Jefferies Financial Group lowered their target price on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a report on Friday, April 17th. Mizuho cut their price target on Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Raymond James Financial reduced their price objective on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Finally, Weiss Ratings upgraded Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $118.42.

Get Our Latest Stock Analysis on Abbott Laboratories

Abbott Laboratories Stock Down 0.8%

Abbott Laboratories stock opened at $95.12 on Thursday. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The company has a fifty day simple moving average of $89.15 and a 200 day simple moving average of $103.53. The company has a market cap of $165.68 billion, a P/E ratio of 26.64, a price-to-earnings-growth ratio of 1.65 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. During the same period in the previous year, the firm posted $1.09 EPS. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Research analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.6%. Abbott Laboratories’s dividend payout ratio is 70.59%.

Insider Activity at Abbott Laboratories

In related news, Director Daniel J. Starks purchased 10,000 shares of the firm’s stock in a transaction on Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the purchase, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Philip P. Boudreau purchased 2,200 shares of the stock in a transaction on Thursday, April 23rd. The shares were bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the transaction, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 0.46% of the company’s stock.

About Abbott Laboratories

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.